

Supporting Information

Xu et al. 10.1073/pnas.0914061107

Table S1. Clinical and demographic characteristics of subjects in CAPS

Characteristic	No. (%) of cases			No. (%) of controls (n = 1,722)
	Aggressive (n = 1,231)	Localized (n = 1,619)	All cases (n = 2,899)	
Age at enrollment (y)				
Mean (SD)	68.04 (7.32)	65.14 (6.74)	66.36 (7.13)	67.15 (7.39)
Age, y, at diagnosis				
65	514 (41.75)	926 (57.19)	1469 (50.78)	N/A
>65	717 (58.25)	693 (42.81)	1424 (49.22)	N/A
Family history (first-degree relatives)				
No	1013 (82.29)	1295 (79.99)	2,342 (80.95)	1,565 (90.57)
Yes	218 (17.71)	324 (20.01)	551 (19.05)	163 (9.43)
Missing data	0	0	0	0
PSA levels at diagnosis for cases or at enrollment for controls (ng/mL)				
4	36 (2.95)	185 (11.61)	221 (7.85)	1,438 (83.56)
4.01–9.99	171 (14.00)	755 (47.39)	926 (32.91)	230 (13.36)
10–19.99	216 (17.69)	438 (27.50)	654 (23.24)	37 (2.15)
20–49.99	252 (20.64)	215 (13.50)	467 (16.60)	13 (0.76)
50–99.99	229 (18.76)	0	229 (8.14)	2 (0.12)
100	317 (25.96)	0	317 (11.27)	1 (0.06)
Missing	10	26	85	1
T-stage				
T0	2 (0.16)	7 (0.44)	9 (0.32)	N/A
T1	147 (12.07)	933 (58.24)	1080 (38.30)	N/A
T2	242 (19.87)	662 (41.32)	904 (32.06)	N/A
T3	724 (59.44)	0	724 (25.67)	N/A
T4	103 (8.46)	0	103 (3.65)	N/A
TX	13	17	79	N/A
N-stage				
N0	222 (70.03)	302 (100.00)	524 (84.65)	N/A
N1	95 (29.97)	0	95 (15.35)	N/A
NX	914	1317	2280	N/A
M-stage				
M0	589 (68.25)	655 (100.00)	1244 (81.95)	N/A
M1	274 (31.75)	0	274 (18.05)	N/A
MX	368	964	1381	N/A
Gleason (biopsy)				
4	9 (0.83)	98 (6.32)	107 (4.06)	N/A
5	43 (3.96)	247 (15.93)	290 (10.99)	N/A
6	153 (14.08)	832 (53.64)	985 (37.34)	N/A
7	414 (38.09)	374 (24.11)	788 (29.87)	N/A
8	258 (23.74)	0	258 (9.78)	N/A
9	185 (17.02)	0	185 (7.01)	N/A
10	25 (2.30)	0	25	N/A
Missing	144	68	261	N/A

Forty-nine patients could not be classified as having aggressive or localized disease because of missing phenotypes.

Table S2. Clinical and demographic characteristics of study subjects

Characteristic	No. (%) of cases			Controls (n = 482)
	Aggressive (n = 1,408)	Indolent (n = 4,318)	All cases (n = 5,955)	
Age at enrollment (y)				
Mean (SD)	59.8 (6.72)	57.7 (6.49)	58.3 (6.69)	59.91 (7.19)
Age at diagnosis (y)				
≤65	1,112 (78.98)	3,833 (88.77)	5,115 (85.89)	
>65	296 (21.02)	485 (11.23)	839 (14.09)	
PSA levels at diagnosis for cases or at enrollment for controls (ng/mL)				
≤4	139 (9.87)	1,095 (25.36)	1,262 (21.19)	481 (99.79)
4.01–9.99	611 (43.39)	2,264 (52.43)	2,951 (49.55)	0
10–19.99	182 (12.93)	247 (5.72)	451 (7.57)	0
20–49.99	84 (5.97)	36 (0.83)	131 (2.2)	0
50–99.99	34 (2.41)	4 (0.09)	58 (0.97)	0
≥100	63 (4.47)	3 (0.07)	117 (1.96)	0
Missing	196 (13.92)	669 (15.49)	985 (16.54)	1 (0.21)
T-stage				
T0	NA	NA	NA	NA
T1	NA	NA	NA	NA
T2	368 (26.14)	3,416 (79.11)	3,850 (64.65)	NA
T3a	536 (38.07)	902 (20.89)	1,454 (24.42)	NA
T3b/c	355 (25.21)	0	355 (5.96)	NA
T3/T3X	9 (0.64)	0	15 (0.25)	NA
T4	3 (0.21)	0	3 (0.05)	NA
TX	137 (9.73)	0	278 (4.67)	NA
N-stage				
N0	1,085 (77.06)	4,318 (100)	5,469 (91.84)	NA
N1	140 (9.94)	0 (0)	140 (2.35)	NA
NX	183 (13)	0 (0)	346 (5.81)	NA
M-stage				
M0	NA	NA	NA	NA
M1	NA	NA	NA	NA
MX	1,408	4,318	5,955	NA
Gleason score (biopsy)				
≤4	0	0	2 (0.03)	NA
5	2 (0.14)	67 (1.55)	73 (1.23)	NA
6	23 (1.63)	3,042 (70.45)	3,104 (52.12)	NA
7 (3+4)	106 (7.53)	1,254 (29.04)	1,411 (23.69)	NA
7(4+3)	667 (47.37)	0	667 (11.2)	NA
8	317 (22.51)	0	317 (5.32)	NA
9	265 (18.82)	0	265 (4.45)	NA
10	18 (1.28)	0	18 (0.3)	NA
Missing	10 (0.71)	0	98 (1.65)	NA

A total of 229 patients could not be classified as having aggressive or indolent disease because of missing phenotypes.

